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Background. The EUMDS registry is an unique
prospective, longitudinal observational registry
enrolling newly diagnosed patients with lower-risk
myelodysplastic syndrome (MDS) from 17 Euro-
pean countries from both university hospitals and
smaller regional hospitals.
Objective. The aim of this study was to describe the
usage and clinical impact of erythropoiesis-stimu-
lating agents (ESAs) in 1696 patients enrolled
between 2008 and 2014.
Methods. The effects of ESAs on outcomes were
assessed using proportional hazards models
weighting observations by propensity to receive
ESA treatment within a subset of anaemic
patients with or without a regular transfusion
need.
Results. ESA treatment (median duration of
27.5 months, range 0–77 months) was adminis-
tered to 773 patients (45.6%). Outcomes were
assessed in 897 patients (484 ESA treated and
413 untreated). ESA treatment was associated
with a nonsignificant survival benefit (HR 0.82,
95% CI: 0.65–1.04, P = 0.09); this benefit was
larger amongst patients without prior transfu-
sions (P = 0.07). Amongst 539 patients for whom
response to ESA treatment could be defined,
median time to first post-ESA treatment transfu-
sion was 6.1 months (IQR: 4.3–15.9 months) in
those transfused before ESA treatment compared
to 23.3 months (IQR: 7.0–47.8 months) in
patients without prior transfusions (HR 2.4,
95% CI: 1.7–3.3, P < 0.0001). Responding
patients had a better prognosis in terms of a
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lower risk of death (HR 0.65, 95% CI: 0.45–
0.893, P = 0.018), whereas there was no signifi-
cant effect on the risk of progression to acute
myeloid leukaemia (HR 0.71, 95% CI: 0.39–1.29,
P = 0.27).
Conclusion. Appropriate use of ESAs can significantly
delay the onset of a regular transfusion need in
patients with lower-risk MDS.
Keywords: anaemia, haematology, haemoglobin,
MDS, Myelodysplasia.
Introduction
Lower-risk myelodysplastic syndrome (MDS) is a
malignant condition that is treated at both Medi-
cine and Haematology Departments in small and
large hospitals. The anaemia of patients with
lower-risk MDS has been associated with reduced
quality of life in a number of small prospective
Phase II trials [1–4] and with reduced survival in
retrospective registry reports [5]. Current guideli-
nes recommend erythropoiesis-stimulating agents
(ESAs) as first-line treatment for patients with low-
and intermediate-1-risk MDS with symptomatic
anaemia [6–10]; however, the effect on long-term
outcome in population-based unselected cohorts is
unknown. In recent studies, overall response rates
varied between 38.0% and 65.5%, with a median
response duration of around 20 months [2, 5, 11,
12]. The efficacy of erythropoietin (EPO) can be
enhanced by the addition of granulocyte colony-
stimulating factor (G-CSF), mainly in MDS with
ring sideroblasts; the median duration of response
to the combined treatment is around 30 months,
with some patients responding for more than
10 years [1]. Patients with a low probability of
response are characterized by a transfusion need
exceeding 2 units per month combined with a
serum EPO level of ≥500 U L1 [3]. However, some
studies have shown that the effect of ESAs is
decreased already at serum EPO levels of
>100 U L1 [5, 11, 13].
The French MDS (GFM) group compared overall
survival in patients treatedwithESAswithin clinical
studieswith patients in the International Prognostic
Scoring System (IPSS) database and showed a
longer survival in the treated group [5]. In another
study, the same group reported that onset of a
regular transfusion need was delayed if EPO treat-
ment was started within 6 months of diagnosis [13].
Another large retrospective study compared the
outcome of patients treated within the Nordic EPO
+ G-CSF studies 1990–1999 with that of untreated
patients from the Italian Pavia registry recruited
during the same period [2]. The groups were
matched for all major risk variables and very few
patients received chelation treatment. Survival was
markedly better in the group exposed to ESAs (RR
0.61, 95% CI: 0.44–0.83, P < 0.002) with no differ-
ence in transformation to acute myeloid leukaemia
(AML). In a prospective clinical trial comparing EPO
to supportive care in patients with lower-risk MDS,
the response rate was better in the EPO arm (36.0%
vs. 9.6%) but the crossover design of the study
prevented assessment of long-term survival [14].
The European LeukaemiaNet MDS (EUMDS) reg-
istry is an unique, prospective, noninterventional
longitudinal registry enrolling patients with lower-
risk MDS within 3 months of diagnosis from 17
countries across Europe [15]. Therapy is given
according to local guidelines. The main objective of
this study was to explore the effects of ESAs on
outcomes amongst patients with anaemia. The
major and clinically highly relevant finding was
that ESAs significantly prolong the time to first
post-ESA treatment transfusions in previously
untransfused patients.
Methods and materials
Subjects
Patients newly diagnosed with IPSS low- or inter-
mediate-1-risk primary MDS from university hos-
pitals aswell as fromsmaller regional units in awide
range of European countries were invited to partic-
ipate as described elsewhere [15]. Start and stop
dates of treatment with ESAs or other MDS-specific
therapies, laboratory measurements, concomitant
disease, medications and quality of lifemetrics were
recorded approximately every 6 months until death
or withdrawal from the study. Recruitment is ongo-
ing with 1863 patients enrolled up to 16 April 2015.
National ethics committees have approved the
study, and all patients provided written informed
consent for inclusion in the registry. At the start of
the study, IPSSwas the score system inuse and only
patientswith IPSS lowor intermediate-1 scoreswere
registered. The revised score (IPSS-R)has sincebeen
established as the prefered scoring system and has
been used in the present analyses including all
registered patients despite some being identified by
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the IPSS-R as not having low- or intermediate-risk
disease.
ESA usage patterns
The patterns of ESA usage in the registry were
described using univariable logistic regression.
Only those patients diagnosed before 1 April 2014
(treatment usage group, n = 1696; Fig. 1) were
included to avoid misclassification of ESA treat-
ment.
Response to ESA treatment
It was not possible to define response to ESAs by
the International Working Group (IWG) 2006 cri-
teria [16] as blood count data and transfusion
information were recorded only every 6 months.
Instead, response criteria were modelled on those
of the Nordic [1, 17] and French [5] MDS groups.
Briefly, patients were defined as responders if their
haemoglobin (Hb) increased by at least 1.5 g dL1
compared to the pre-ESA treatment level. Addi-
tionally, patients who received transfusions prior
to ESA treatment were defined as responders if no
transfusions were administered between 8 and
16 weeks after receiving ESAs. Response rates
were therefore underestimated using these com-
pared to the IWG criteria (Supplementary mate-
rial). Stopping ESA treatment within 8 weeks was
interpreted as failure to respond. Importantly,
remaining transfusion-independent if ESA treat-
ment was started prior to receiving any transfu-
sions was not considered a response criterion.
Fig. 1 CONSORT diagram showing relationship between the groups of patients included in the different analyses
presented in this study. The treatment pattern of erythropoiesis-stimulating agents (ESAs) in different European countries
was described for 1696 patients (773 ESA-treated and 923 without ESA treatment). A total of 897 patients (484 ESA-treated
and 413 untreated) were retained for the propensity model group. The effect of ESA treatment on survival and disease
progression was assessed only amongst the 860 analysed patients of the outcome group whose propensity scores for
receiving ESA treatment were in the overlapping region of the propensity score distributions of treated and untreated
patients. 1Patients with propensity scores outside the overlapping region denoted by the dashed lines in Fig. 4a. Hb,
haemoglobin.
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Response could be defined for 69.7% (n = 539) of
all ESA-treated patients. Direct adjustment of
proportional hazards models for covariates (Sup-
plementary material) was used to compare time-to-
event outcomes of responding and nonresponding
ESA-treated patients.
Effect of ESA treatment on patient outcomes
The effect of ESA treatment on survival and
progression to AML was assessed amongst patients
with a stable or a pretransfusion Hb value
<10 g dL1 at a visit before 1 April 2014
(n = 996). Patients starting ESAs >30 days prior
to diagnosis with MDS (n = 12) and those only
eligible for inclusion at their last recorded visit
(n = 87) were excluded from this analysis, leaving
897 patients in the propensity model group (Fig. 1).
To overcome potential confounding by nonrandom
allocation of ESA treatment, proportional hazards
regression models comparing time-to-event out-
comes in treated and untreated patients were
weighted [18] by stabilized inverse probability of
treatment weights [19] based on the propensity of a
patient to receive ESA treatment. No further
adjustments were included. Propensity to receive
ESA treatment was modelled using multivariate
logistic regression (Supplementary material). Only
patients with comparable propensity scores were
included in the analyses to estimate the effects of
ESA treatment on outcomes (outcome group:
n = 860; 474 treated and 386 not treated with
ESAs; Fig. 1). The relationship between the effects
of ESAs and pre-ESA treatment transfusion status
was explored with this model.
All analyses were performed using the SAS/STAT
software (SAS Institute Inc., Cary, NC, USA) [20],
and tests of the proportional hazards assumption
were undertaken in all analyses.
Results
Baseline characteristics of the cohort
The present analysis included 1696 patients diag-
nosed between January 2008 and April 2014
(Fig. 1). The median age at diagnosis was
74.4 years (range 18.7–95.3 years). The median
follow-up time amongst these patients, estimated
by the reverse Kaplan–Meier method [21], was
3.7 years from diagnosis (range 0–7.0 years; 11
patients were included and censored on the date of
diagnosis).
There was an overall male bias amongst the
patients (61.0% men) in all World Health Organi-
zation (WHO) diagnostic groups with the exception
of 5q-syndrome (83.0% women). Amongst these
diagnostic groups, refractory cytopenia with mul-
tilineage dysplasia (RCMD) was diagnosed most
frequently (37.8%) followed by refractory anaemia
(RA) (17.6%), RA with ring sideroblasts (RARS)
(16.7%), RA with excess blasts (RAEB)-1 (12.3%),
5q-syndrome (6.1%), RCMD with ring sideroblasts
(RCMD-RS) (5.8%) and RAEB-2 (0.4%). A further
3.2% (55 patients) had unclassified MDS (Table 1).
The majority of patients were classified as low
(42.1%) or very low (24.9%) risk according to the
IPSS-R (Table 1), with 15.0% classified as interme-
diate risk and 4.1% as high or very high risk and
13.0% were unclassified (<5% blasts and only one
significant cytopenia).
Variation in the use of ESAs within Europe
In total, 773 patients (45.6% of all patients) were
treated with ESAs, 57.8% of whom were male.
Mean age in the treated and untreated groups were
71.7 and 74.3 years, respectively. Treated patients
were older, and patients with higher MDS comor-
bidity index scores were more likely to receive ESAs
than patients with low scores.
The proportion receiving ESAs varied by WHO
classification and was highest amongst patients
with RCMD-RS (63.6%) and lowest amongst those
with RCMD (36.3%; Table 1). ESA use was lowest
in patients with a very low-risk score (36.6%;
Table 1). ESA use varied significantly between
countries (Table 1), and there was no obvious
relationship with national gross domestic product
(GDP) (Fig. 2a) [22]. Of all patients treated with
EPO, 16.3% received parallel treatment with G-
CSF; patients with RCMD-RS (27.0%) and RARS
(20.9%) were the most likely to receive G-CSF in
addition to EPO, in line with previous reports [1, 2].
Amongst patients who started ESAs after diagno-
sis, the median time to treatment was 2.3 months
(IQR: 0.9–7.6 months; Fig. 2b). The mean Hb value
before the start of ESA treatment was 9.1 g dL1
(range 3.0–14.9 g dL1; Fig. 2c) with a substantial
variation between countries. At the start of ESA
treatment, 558 (72.2%) patients were defined as
anaemic (Hb < 10 g dL1 according to the WHO
criteria); 287 of these patients received transfu-
sions prior to starting ESAs. Of the remaining 215
ESA-treated patients (27.8%), 160 patients started
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Table 1 Baseline characteristics of patients diagnosed before 1 April 2014 showing distribution of factors by treatment with
erythropoietin-stimulating agents (ESA) and the association between each factor and the probability of receiving ESAs in a
univariable logistic regression model
Total (% of total)
ESA use
Odds ratio
(95% confidence interval)
Likelihood ratio
P-value
Treated
(% of group)
Not treated
(% of group)
Total 1696 (100) 773 (45.6) 923 (54.4)
Age at diagnosis (years)
<60 190 (11.2) 62 (8.0) 128 (13.9) 0.48 (0.35, 0.67) <0.0001
60–74 703 (41.5) 309 (40.0) 394 (42.7) 0.78 (0.64, 0.96)
75+ 803 (47.4) 402 (52.0) 401 (43.5) 1 (reference)
Sex
Female 662 (39.0) 326 (42.2) 336 (36.4) 1.27 (1.05, 1.55) 0.015
Male 1034 (61.0) 447 (57.8) 587 (63.6) 1 (reference)
MDS diagnosis (WHO 2008)
RA 299 (17.6) 158 (20.4) 141 (15.3) 1.96 (1.49, 2.59) <0.0001
RARS 283 (16.7) 163 (21.1) 120 (13.0) 2.38 (1.79, 3.16)
RCMD 641 (37.8) 233 (30.1) 408 (44.2) 1 (reference)
RCMD-RS 99 (5.8) 63 (8.2) 36 (3.9) 3.06 (1.97, 4.76)
RAEB-1 or RAEB-2 216 (12.7) 79 (10.2) 137 (14.8) 1.01 (0.73, 1.39)
MDS-U 55 (3.2) 21 (2.7) 34 (3.7) 1.08 (0.61, 1.91)
5q-syndrome 103 (6.1) 56 (7.2) 47 (5.1) 2.09 (1.37, 3.17)
IPSS-R risk category
Very low 423 (24.9) 155 (20.1) 268 (29.0) 0.48 (0.38, 0.62) <0.0001
Low 714 (42.1) 389 (50.3) 325 (35.2) 1 (reference)
Intermediate 270 (15.9) 120 (15.5) 150 (16.3) 0.67 (0.5, 0.89)
High/very high 69 (4.1) 30 (3.9) 39 (4.2) 0.64 (0.39, 1.06)
Unknown 220 (13.0) 79 (10.2) 141 (15.3) 0.47 (0.34, 0.64)
Country
Austria 95 (5.6) 31 (4.0) 64 (6.9) 0.42 (0.26, 0.67) <0.0001
Croatia 3 (0.2) 0 (0.0) 3 (0.3) –
Czech Republic 124 (7.3) 39 (5.1) 85 (9.2) 0.39 (0.26, 0.6)
Denmark 41 (2.4) 29 (3.8) 12 (1.3) 2.07 (1.03, 4.17)
France 403 (23.8) 217 (28.1) 186 (20.2) 1 (reference)
Germany 48 (2.8) 13 (1.7) 35 (3.8) 0.32 (0.16, 0.62)
Greece 155 (9.1) 86 (11.1) 69 (7.5) 1.07 (0.74, 1.55)
Israel 74 (4.4) 38 (4.9) 36 (3.9) 0.9 (0.55, 1.49)
Italy 64 (3.8) 28 (3.6) 36 (3.9) 0.67 (0.39, 1.13)
Netherlands 44 (2.6) 14 (1.8) 30 (3.3) 0.4 (0.21, 0.78)
Poland 49 (2.9) 16 (2.1) 33 (3.6) 0.42 (0.22, 0.78)
Portugal 35 (2.1) 17 (2.2) 18 (2.0) 0.81 (0.41, 1.62)
Republic of Serbia 11 (0.7) 0 (0.0) 11 (1.2) –
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ESAs at a level of ≥10 g dL1 Hb; the Hb level
before the start of ESA treatment was not available
in 22 patients and reflected previous transfusions
in 33 patients. Once initiated, patients stayed on
ESA treatment for a median of 27.5 months (range
0–77.0 months).
Better long-term outcome in patients with a response to ESA
treatment
Using the criteria described in the Methods, a
response to treatment could be assessed in 539 of
the 773 ESA-treated patients (69.7%) with 286
(53.1%) patients achieving a response, including
19 patients with ≥10 g dL1 Hb at the start of ESA
treatment and with an increase in Hb of
≥1.5 g dL1. Responding patients had a better
prognosis in terms of a lower risk of death (HR
0.65, 95% CI: 0.45–0.893, P = 0.018), whereas
there was no significant effect on the risk of
progression to AML (HR 0.71, 95% CI: 0.39–1.29,
P = 0.27). The proportion of patients with an
increase in Hb ≥1.5 g dL1, or for whom blood
transfusions were no longer required between 8
and 16 weeks after the start of ESA treatment
varied depending on pre-ESA treatment transfu-
sion status: 26.7% and 74.2% amongst patients
without and with pre-ESA treatment transfusions,
respectively. This is likely to reflect the fact that Hb
levels were only recorded every 6 months, whereas
all transfusions between visits were reported. When
only a positive effect on Hb was taken as an
indication of response, the response rate amongst
thosewithnopre-ESA treatment transfusions (27%)
was comparable to the rate amongst those who
received transfusions before ESA treatment (28%).
Response to ESA treatment is associated with a delayed need for
transfusion
When analysing patients irrespective of their pre-
ESA treatment transfusion status, time to the first
post-ESA treatment transfusion was longer
amongst patients responding to ESAs (median
transfusion-free time 11.9 months) than amongst
nonresponders (median 7.1 months; HR 0.43, 95%
CI: 0.32–0.57, P < 0.0001; Fig. 3a). The effect of
response on time to first post-ESA treatment
transfusion remained also after stratification by
pretreatment transfusion experience (Fig. 3b).
Importantly, and irrespective of response status,
patients who received transfusions before starting
ESAs had a shorter time to their first post-
treatment transfusion (median 6.1 vs.
23.3 months for nontransfused patients; HR 2.4,
95% CI: 1.75–3.31, P < 0.0001). Serum EPO mea-
surements at or near the start of ESA treatment
were available for 271 of the 539 patients (50.3%)
Table 1 (Continued )
Total (% of total)
ESA use
Odds ratio
(95% confidence interval)
Likelihood ratio
P-value
Treated
(% of group)
Not treated
(% of group)
Romania 40 (2.4) 24 (3.1) 16 (1.7) 1.29 (0.66, 2.49)
Spain 131 (7.7) 71 (9.2) 60 (6.5) 1.01 (0.68, 1.51)
Sweden 107 (6.3) 69 (8.9) 38 (4.1) 1.56 (1.00, 2.42)
UK 272 (16.0) 81 (10.5) 191 (20.7) 0.36 (0.26, 0.5)
MDS, myelodysplastic syndrome; ESA, erythropoiesis-stimulating agent; WHO, World Health Organization; RA, refractory
anaemia; RARS, refractory anaemia with ring sideroblasts; RCMD, refractory cytopenia with multilineage dysplasia;
RCMD-RS, refractory cytopenia with multilineage dysplasia and ringed sideroblasts; RAEB, refractory anaemia with
excess blasts; MDS-U, myelodysplastic syndrome, unclassifiable; IPSS-R, revised International Prognostic Scoring
System.
Fig. 2 The use of erythropoiesis-stimulating agents (ESAs) in a European low-risk myelodysplastic syndrome (MDS)
registry. (a) Proportion of registered patients receiving ESAs relative to the 2013 national gross domestic product (GDP)
(source: http://www.imf.org/external/pubs/ft/weo/2014/02/weodata/index.aspx) showing no apparent relationship
(bubble size is proportional to the number of registered patients shown in Table 1). (b) Most patients start ESA treatment
relatively soon after diagnosis. (c) The haemoglobin (Hb) level at or near the start of treatment with ESAs amongst treated
patients in participating countries was usually below the eligibility criteria of 10 g dL1 (dashed line).
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with a defined response; median serum EPO
amongst 153 responders (72.7 U L1, IQR: 30–
168 U L1) was lower than amongst 118
nonresponders (100 U L1, IQR: 38.4–218 U L1);
however, the difference was not significant (two-
sided Wilcoxon test, P = 0.113).
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Fig. 3 Comparison of time to first posterythropoiesis-stimulating agent (ESA) treatment transfusion between ESA-treated
patients who did or did not respond to ESAs. (a) Time to first post-ESA treatment transfusion was significantly improved
amongstpatients responding toESA treatment compared to thosenot responding (HR0.43,95%CI: 0.32–0.57,P < 0.0001). (b)
The response effect on time to first post-ESA transfusionwas evidentwhen stratified by pre-ESA transfusion experience (solid
line versus long-dashed line for untransfused patients and short-dashed line versus dotted line for transfused patients).
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Effect of ESA treatment on overall survival and risk of AML
progression
In total, 897 patients (484 ESA treated and 413
untreated) were included in the propensity model
group (Fig. 1). The strongest predictors of receiving
ESAs were country and having a lower serum EPO
level (Tables 2 and 3). The distributions of the
propensity scores of ESA-treated and untreated
patients differed to a certain degree (Fig. 4a) but
restricting the data set to treated and untreated
patients with comparable propensity scores resulted
in the loss of only 37 patients (Fig. 1) leaving 860
patients in the outcome group available for assess-
ment of the effect of ESAs ondisease progression and
survival. Weighted comparisons of covariates in the
propensity model (Tables 2 and 3) showed no differ-
ences between ESA-treated and untreated patients.
A nonsignificant beneficial effect of ESA treatment
on overall survival was estimated (HR 0.82, 95%
CI: 0.65–1.04, P = 0.09; Fig. 4b) from the weighted
regression model comparing patients with compa-
rable propensity scores (Figs 1 and 4a). Progres-
sion to AML or high-risk MDS was observed for 77
(16.2%) of the ESA-treated patients and 66 (17.1%)
of those not receiving ESAs; a nonsignificant esti-
mate of a beneficial effect of ESA treatment was
obtained (HR 0.88, 0.63–1.22, P = 0.44; Fig. 4c).
The relationship between ESA treatment and pre-
treatment transfusion status was explored and
revealed a larger estimated effect of ESAs on
survival amongst patients who had not received
transfusions prior to starting ESA treatment
(treated compared to untreated: HR 0.71, 95% CI:
0.49–1.03, P = 0.07) than amongst patients who
had received prior transfusions (treated compared
to untreated: HR 0.93, 95% CI: 0.70–1.26,
P = 0.67; Fig. 4d). The interaction between the
effects did not add significantly to the regression
model. Similar results were found when consider-
ing progression to AML (data not shown).
Discussion
The aim of this study was to analyse treatment
patterns of ESAs, as well as their effects on long-
term outcome in a large prospectively enrolled and
well followed-up cohort of patients with lower-risk
MDS. Because of the recruitment of patients from
university hospitals as well as from smaller regio-
nal units in a wide range of European countries,
our data can be viewed as representative of MDS
patients in routine clinical practice. The higher
median age of patients in the EUMDS registry
(74.4 years) compared to other registries with a
majority of patients from university hospitals (e.g.
D€usseldorf, 72 years; Pavia, 65.3 years [23, 24])
may be due to the wider recruitment. It may also be
a reflection of an ageing population given the more
recent establishment of the EUMDS registry.
Our results revealed marked variations in ESA use
across Europe. Most but not all countries follow
guidelines as recently proposed by the European
LeukemiaNet [8]. However, in some countries,
transfusion need is a prerequisite for treatment
initiation, an approach that is not supported by the
findings of this analysis. Financial restrictions are
placed on ESA use in certain countries including
Poland, UK, the Netherlands and Greece, but
overall, there was no apparent association between
GDP and the use of ESAs, indicating that other
factors also influence the therapeutic decision.
Furthermore, there were marked variations in
pre-ESA treatment Hb levels between the coun-
tries, with Sweden and the Netherlands starting
ESAs at higher Hb levels than for example Portu-
gal, Poland and Romania, where patients were
usually transfusion-dependent before the start of
treatment. It is interesting that across most coun-
tries, ESA treatment was more common amongst
patients with, compared to those without, ring
sideroblasts, reflecting a higher rate of symp-
tomatic anaemia in this patient group but also
more frequent use of other treatments, such as
lenalidomide, in nonsideroblastic cases.
As Hb levels and number of transfusions were only
assessed every 6 months, subtle changes in trans-
fusion need and Hb levels used to identify haema-
tological improvement as defined by IWG 2006
criteria [16] were not considered possible to assess.
As a consequence of this, as response to ESAs is
usually achieved within 8–12 weeks of starting
treatment, subjects in the registry whose response
had a duration of less than 6 months may have
been misclassified as nonresponders using these
criteria. Importantly, using these strict criteria,
response rates are predicted to be lower than in
prospective clinical trials. With this in mind, it is
important to note that as high a proportion as 28%
of transfusion-dependent patients achieved both
transfusion independency and a clear increase in
Hb levels in response to treatment. The median
treatment duration of 27.5 months indicates
response duration of around 2 years, in line with
previous reports [2]. The responders received ESAs
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Table 2 Outcome group: distribution of select categorical factors amongst 484 ESA-treated and 413 untreated patients
showing adjusted odds ratios and likelihood ratio test P-values of the covariate effects from amultivariate logistic regression
model of the propensity to receive ESA treatment
Level Total (%) Treated (%) Untreated (%) OR (95% CI) Likelihood ratio test P-value
Total 897 (100) 484 (100) 413 (100) – –
Sex
Female 379 (42.3) 206 (42.6) 173 (41.9) 0.96 (0.69, 1.35) 0.834
Male 518 (57.7) 278 (57.4) 240 (58.1) 1 (reference)
MDS diagnosis (WHO 2008)
RA 135 (15.1) 87 (18.0) 48 (11.6) 0.53 (0.24, 1.17) 0.646
RCMD 336 (37.5) 154 (31.8) 182 (44.1) 0.41 (0.21, 0.83)
RARS 161 (17.9) 104 (21.5) 57 (13.8) 0.69 (0.33, 1.47)
RCMD-RS 58 (6.5) 40 (8.3) 18 (4.4) 1 (reference)
RAEB-1 or -2 111 (12.4) 50 (10.3) 61 (14.8) 0.26 (0.09, 0.81)
MDS-U 26 (2.9) 11 (2.3) 15 (3.6) 0.32 (0.10, 0.96)
5q- syndrome 70 (7.8) 38 (7.9) 32 (7.7) 0.41 (0.17, 0.97)
IPSS-R categorya
Very low 129 (14.4) 60 (12.4) 69 (16.7) 1 (reference) 0.242
Low 429 (47.8) 261 (53.9) 168 (40.7) 1.69 (1.04, 2.74)
Intermediate 168 (18.7) 83 (17.1) 85 (20.6) 1.40 (0.76, 2.59)
High/very high 57 (6.4) 24 (5.0) 33 (8.0) 1.21 (0.50, 2.90)
Unknown 114 (12.7) 56 (11.6) 58 (14.0) 1.23 (0.66, 2.28)
Bone marrow blastsa
<5% 781 (87.1) 428 (88.4) 353 (85.5) 1 (reference) 0.337
5–10% 116 (12.9) 56 (11.6) 60 (14.5) 1.59 (0.61, 4.14)
Serum erythropoietinbIU L1
≤32.4 87 (9.7) 52 (10.7) 35 (8.5) 1.64 (0.8, 3.36) 0.008
>32.4 to ≤64.0 91 (10.1) 53 (11.0) 38 (9.2) 1.42 (0.70, 2.91)
>64.0 to ≤141.9 95 (10.6) 63 (13.0) 32 (7.7) 2.47 (1.23, 4.95)
>141.9 to ≤339.0 93 (10.4) 55 (11.4) 38 (9.2) 2.93 (1.44, 5.97)
>339.0 93 (10.4) 41 (8.5) 52 (12.6) 1 (reference)
Missing 438 (48.8) 220 (45.5) 218 (52.8) 1.23 (0.70, 2.16)
Transfusions prior to ESA treatment
No 424 (47.3) 221 (45.7) 203 (49.2) 0.92 (0.64, 1.32) 0.656
Yes 473 (52.7) 263 (54.3) 210 (50.8) 1 (reference)
MDS comorbidity indexb
Low 396 (44.1) 203 (41.9) 193 (46.7) 1 (reference) 0.705
Intermediate 328 (36.6) 190 (39.3) 138 (33.4) 1.06 (0.69, 1.62)
High 173 (19.3) 91 (18.8) 82 (19.9) 0.88 (0.55, 1.40)
Dyspnoea levelb
None 756 (84.3) 408 (84.3) 348 (84.3) 0.61 (0.27, 1.39) 0.221
Moderate 100 (11.1) 52 (10.7) 48 (11.6) 0.58 (0.23, 1.46)
Slight 36 (4.0) 23 (4.8) 13 (3.1) 1 (reference)
Rest 5 (0.6) 1 (0.2) 4 (1.0) 0.08 (0.01, 0.94)
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for a median duration of 38.3 months (IQR: 12.0–
63.6 months), whereas nonresponders were trea-
ted for a median duration of 15.0 months (IQR:
3.3–44.6 months).
In most clinical trials and therapeutic guidelines,
serum EPO appears to be a predictor of response to
ESA treatment [3]. This was also the case amongst
those patients with available serum EPO measure-
ments in this study, with only a few patients having
serum EPO levels above 200 U L1.
An important conclusion of this large observational
registry study is that the response rate to ESAs as
well as the capacity of these agents to significantly
delay the onset of a regular transfusion need ismost
pronounced in transfusion-na€ıve patients, thus
corroborating the findings from a small retrospec-
tive study by the French GFM group [13]. It could
also be assumed that disease is more severe in
patients with an urgent transfusion need and thus
these patients are less likely to respond to ESAs;
however, because several countries require a trans-
fusionneedbefore startingESA treatment, it is likely
that these differences partly reflect the fact that
transfusion-na€ıve patients are more responsive. In
exploratory analyses, patients with a transfusion
requirement of less than 2 units per month showed
a pattern closer to that of the untransfused rather
than transfused patients, but the groups were too
small toallow for robust statistical comparison (data
not shown). Clearly it would be desirable to prove
this relationship in a prospective randomized study,
but such a study would be difficult to conduct.
Hence, we propose that ESAs should be recom-
mended as first-line treatment in low-risk MDS
patients with symptomatic anaemia before starting
regular transfusions.
The plausibility of a country-specific analysis was
investigated; however, only two countries had
sufficient comparable treated and untreated
patients and therefore this issue may be consid-
ered in the future as the registry matures.
Table 2 (Continued )
Level Total (%) Treated (%) Untreated (%) OR (95% CI) Likelihood ratio test P-value
Country
Austria 45 (5.0) 17 (3.5) 28 (6.8) 1.40 (0.64, 3.07) <0.001
Croatia 2 (0.2) 0 (0.0) 2 (0.5) 0 (–)
Czech Republic 86 (9.6) 29 (6.0) 57 (13.8) 0.66 (0.34, 1.29)
Denmark 30 (3.3) 25 (5.2) 5 (1.2) 9.33 (3.13, 27.76)
France 167 (18.6) 123 (25.4) 44 (10.7) 5.56 (3.33, 9.28)
Germany 28 (3.1) 9 (1.9) 19 (4.6) 0.78 (0.31, 1.99)
Greece 71 (7.9) 52 (10.7) 19 (4.6) 4.64 (2.23, 9.63)
Israel 33 (3.7) 22 (4.5) 11 (2.7) 4.15 (1.65, 10.43)
Italy 25 (2.8) 15 (3.1) 10 (2.4) 2.88 (1.08, 7.67)
Netherlands 21 (2.3) 6 (1.2) 15 (3.6) 0.70 (0.24, 2.05)
Poland 35 (3.9) 11 (2.3) 24 (5.8) 0.76 (0.32, 1.86)
Portugal 24 (2.7) 15 (3.1) 9 (2.2) 2.41 (0.88, 6.61)
Romania 30 (3.3) 21 (4.3) 9 (2.2) 2.67 (0.96, 7.41)
Republic of Serbia 8 (0.9) 0 (0.0) 8 (1.9) 0 (–)
Spain 61 (6.8) 38 (7.9) 23 (5.6) 2.79 (1.38, 5.64)
Sweden 54 (6.0) 38 (7.9) 16 (3.9) 3.82 (1.78, 8.20)
UK 177 (19.7) 63 (13.0) 114 (27.6) 1 (reference)
aAt diagnosis; bat the start of ESA treatment.
MDS, myelodysplastic syndrome; ESA, erythropoiesis-stimulating agent; WHO, World Health Organization; RA, refractory
anaemia; RARS, refractory anaemia with ring sideroblasts; RCMD, refractory cytopenia with multilineage dysplasia;
RCMD-RS, refractory cytopenia with multilineage dysplasia and ringed sideroblasts; RAEB, refractory anaemia with
excess blasts; MDS-U, myelodysplastic syndrome, unclassifiable; IPSS-R, revised International Prognostic Scoring
System.
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Previous retrospective epidemiological studies on
cohorts collected within academic trials, compas-
sionate use cohorts and the IPSS database [2, 5,
11] have shown significant survival benefits for
ESA-treated compared with untreated patients. It
is clear that such studies carry inherent problems
regarding patient selection. The prospective non-
interventional EUMDS registry has several advan-
tages and disadvantages but as treatment with
ESAs is based solely on the physician’s choice, it is
most likely to be as close to the real-world setting
as possible, whilst still retaining control over
objective entry and exit variables. As the decision
to start ESA treatment could be based both on a too
favourable clinical status and a too poor likelihood
of responding to ESAs, we chose to base the
outcome analysis on the propensity to receive ESAs
[18]. Our results showed a nonsignificant positive
association between ESA treatment and overall
survival (P = 0.09), but the difference between
ESA-treated and untreated patients was smaller
than that observed in the above-cited large retro-
spective studies.
Our data show that ESA treatment significantly
delays the onset of a permanent transfusion need
in all treated patient groups and in particular if
initiated early. This is an important observation as
a response to treatment with ESAs has been
associated with improved quality of life in several
studies [4, 12, 25]. Moreover, blood transfusion
due to bone marrow failure consumes valuable
resources that could be allocated to other needs
[26].
Despite treatment recommendation in most care
programmes [6–8], this study shows that less than
half of the MDS population receives ESAs at any
time-point. This seems to be due both to national
financial and legal restrictions and to treatment
traditions that do not follow European guidelines.
However, with the marketing of several ESA
biosimilars, the cost-effectiveness of ESAs should
improve with time, thereby shifting usage patterns
towards the international recommendations.
Our findings demonstrate a marked variation in
the usage pattern of recommended first-line treat-
ment for anaemic lower-risk MDS. We conclude
that this leads to clinically significant differences in
the time to onset of a permanent transfusion need.
Whether this has significant long-term effects on
overall survival, disease progression and time to
initiation of other resource-demanding treatments
remains to be investigated. Clearly, the prospective
design of the EUMDS registry provides information
that could not be gained from conventional retro-
spective databases.
Table 3 Distribution of noncategorical covariates amongst 484 ESA-treated and 413 untreated patients, showing the
likelihood ratio test P-values for the covariates included in a logistic regression model of the propensity to receive ESA
treatment
Covariate ESA treatment Mean (SD) Minimum
Percentiles
Maximum
Likelihood ratio test
P-value25th 50th 75th
Age (years)a,b Treated 73.7 (9.3) 41.4 67.9 74.4 80.6 95.3 0.48
Untreated 72.3 (11.1) 21.0 64.9 74.2 80.5 94.0
Time from diagnosis
to ESA start (months)b
Treated 5.8 (9.0) 0.03 0.9 2.0 6.6 60.6 0.48
Untreated 5.8 (9.8) 0 1.1 1.9 6.0 71.6
Haemoglobinb,c Treated 8.5 (1.1) 4.6 7.9 8.7 9.4 10.0 0.29
Untreated 8.5 (1.2) 0.6 7.8 8.7 9.4 10.0
Cytopeniasc,d Treated 1.5 (0.7) 1 1 1 2 3 0.25
Untreated 1.6 (0.7) 1 1 1 2 3
Karnofsky statusb,c,e Treated 81.2 (13.7) 0 70 80 90 100 0.66
Untreated 80.1 (15.5) 0 70 80 90 100
aAt diagnosis; bfitted as b-spline effect; cat the start of ESA treatment; dfitted as a linear effect; eimputed for 76 ESA-
treated and 46 untreated patients using a linear regression model including age at diagnosis, sex, country, the Sorror
score and MDS comorbidity index and, if available, the dimensions and visual analogue score of the EQ-5D questionnaire.
ESA, erythropoiesis-stimulating agent; MDS, myelodysplastic syndrome.
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Fig. 4 The effect of erythropoiesis-stimulating agent (ESA) treatment on survival and progression to acute myeloid
leukaemia (AML). (a) Distribution of propensity scores for ESA-treated (dark grey bars) and untreated (light grey bars)
patients showing upper and lower bounds of the overlapping region (dashed lines). (b) Estimated effect of ESA treatment on
survival (HR 0.82, 95% CI: 0.65–1.03, P = 0.09). (c) Estimated effect of ESA treatment on progression to AML (HR 0.88, 95%
CI: 0.63–1.22, P = 0.43). (d) estimated effect of ESA treatment on survival amongst patients not receiving transfusions
before ESA treatment [treated (solid line) versus untreated (short-dashed line): HR 0.71, 95% CI: 0.49–1.03, P = 0.070] was
greater than amongst those who had at least one pre-ESA treatment transfusion [treated (long-dashed line) versus
untreated (dotted line): HR 0.93, 95% CI: 0.70–1.26, P = 0.67]. There was no significant statistical interaction between
these effects (P = 0.26).
H. K. G. Garelius et al. ESAs in lower-risk MDS
ª 2016 The Authors. Journal of Internal Medicine published by John Wiley & Sons Ltd on behalf of Association for Publication of The Journal of Internal Medicine. 13
Journal of Internal Medicine
Boehringer Ingelheim. S.P. has received research
grants from Novartis, Celgene and Hospira. P.F.
has received honoraria and research funding (as
GFM chairman) from Celgene, Novartis and Amgen
and is on advisory committees for Amgen,
B€oehringer-Ingelheim, Celgene and Janssen. A.S.
has received lecture honoraria, and consultancy
reimbursement from Amgen, Celgene/Gene-
sisPharma, Janssen-Cilag, Gilead, Pfizer, MSD,
Novartis and Genzyme/Sanofi. G.S. has received
honoraria and research funding from Celgene,
Novartis and Amgen and is on advisory committees
for Amgen, Boehringer-Ingelheim, Celgene, Merck
Sharp and Dohme and Novartis. M.M has received
research grants from Celgene (Neopharm), John-
son & Johnson, Novartis, Roche, GSK, Amgen
(Medison). A. A.vdL. has received lecture honoraria
from Celgene and Novartis and a research grant
from Alexion. L.dS. and C.J.vM. are funded by the
EUMDS project budget. T.J.M.dW. has received a
honorarium from Novartis as the project coordina-
tor of the EUMDS study, of which the present
analysis is a part. E.H-L. has received research
funding from Celgene, however, not for this project.
The remaining authors (J.C., R.S. and W.T.J., L.M.,
D.B. and S.C.) declare no competing financial
interests.
Acknowledgements
The authors would like to thank the research
group at Radboud University Medical Center,
Nijmegen for administrative and practical support
all local investigators and operational team mem-
bers for their contribution to the Registry, and
Novartis Pharmacy B.V. Oncology Europe for
financial support. We would like to express
specific thanks to the rest of the EUMDS study
group: Ulrich Germing-Germany; Krzysztof Madry-
Poland; Gerwin Huls-the Netherlands; Aurelia
Tatic-Romania; Mette Skov Holm-Denmark;
Antonio Medina Almeida-Portugal; Aleksandar
Savic-Republic of Serbia; Njetocka Gredelj-Simec-
Croatia; Agnes Guerci-Bresler-France; Elisa Lu~no-
Spain; Odile Beyne-Rauzy-France; and Dominic
Culligan-UK.
Financial support
The work of the EUMDS Registry for low and
intermediate-1 MDS has been supported by an
unrestricted educational grant from Novartis Phar-
macy B.V. Europe. This work is part of the MDS-
RIGHT activities, which has received funding from
the European Union’s Horizon 2020 research and
innovation programme under grant agreement No
634789 - “Providing the right care to the right
patient with MyeloDysplastic Syndrome at the right
time”. W.T.J., A.G.S. and S.C. are supported by
Bloodwise (formerly Leukaemia & Lymphoma
Research). Participants of the EUMDS registry
receive financial support from the European
Union’s Horizon 2020 Research and Innovation
Programme under grant agreement No 634789.
‘Providing the right care to the right patient with
MyeloDysplastic Syndrome at the right time’ (MDS-
RIGHT).
References
1 J€adersten M, Montgomery S, Dybedal I, Porwit-MacDonald A,
Hellstr€om-Lindberg E. Long-term outcome of treatment of
anemia in MDS with erythropoietin and G-CSF. Blood 2005;
106: 803–11.
2 J€adersten M, Malcovati L, Dybedal I et al. Erythropoietin and
granulocyte-colony stimulating factor treatment associated
with improved survival in myelodysplastic syndrome. J Clin
Oncol 2008; 26: 3607–13.
3 Hellstr€om-Lindberg E, Gulbrandsen N, Lindberg G et al. A
validated decision model for treating the anaemia of
myelodysplastic syndromes with erythropoietin + granulocyte
colony-stimulating factor: significant effects on quality of life.
Br J Haematol 2003; 120: 1037–46.
4 Nilsson-Ehle H, Birgegard G, Samuelsson J et al. Quality of
life, physical function and MRI T2* in elderly low-risk MDS
patients treated to a haemoglobin level of ≥120 g/L with
darbepoetin alfa  filgrastim or erythrocyte transfusions. Eur
J Haematol 2011; 87: 244–52.
5 Park S, Grabar S, Kelaidi C et al. Predictive factors of
response and survival in myelodysplastic syndrome treated
with erythropoietin and G-CSF: the GFM experience. Blood
2008; 111: 574–82.
6 Kjeldsen L, Dybedal I, Hellstr€om-Lindberg E et al. Guidelines
for the diagnosis and treatment of Myelodysplastic Syn-
dromes and Chronic Myelomonocytic Leukemia from the
Nordic MDS Group 2014 [updated 1st of February 2014].
2014.
7 Killick SB, Carter C, Culligan D et al. Guidelines for the
diagnosis and management of adult myelodysplastic syn-
dromes. Br J Haematol 2014; 164: 503–25.
8 Malcovati L, Hellstr€om-Lindberg E, Bowen D et al. Diagnosis
and treatment of primary myelodysplastic syndromes in
adults: recommendations from the European LeukemiaNet..
Blood 2013; 122: 2943–64.
9 Greenberg PL, Attar E, Bennett JM et al. Myelodysplastic
syndromes: clinical practice guidelines in oncology. J Natl
Compr Canc Netw 2013; 11: 838–74.
10 Greenberg PL, Stone R, Bejar R et al. Myelodysplastic Syn-
dromes, Version 2.2015. J Natl Compr Canc Netw 2015; 13:
261–72.
11 Kelaidi C, Beyne-Rauzy O, Braun T et al. High response rate
and improved exercise capacity and quality of life with a new
regimen of darbepoetin alfa with or without filgrastim in
H. K. G. Garelius et al. ESAs in lower-risk MDS
14 ª 2016 The Authors. Journal of Internal Medicine published by John Wiley & Sons Ltd on behalf of Association for Publication of The Journal of Internal Medicine.
Journal of Internal Medicine
lower-risk myelodysplastic syndromes: a phase II study by
the GFM. Ann Hematol 2013; 92: 621–31.
12 Balleari E, Clavio M, Arboscello E et al. Weekly standard
doses of rh-EPO are highly effective for the treatment of
anemic patients with low-intermediate 1 risk myelodysplastic
syndromes. Leuk Res 2011; 35: 1472–6.
13 Park S, Kelaidi C, Sapena R et al. Early introduction of ESA in
low risk MDS patients may delay the need for RBC transfu-
sion: a retrospective analysis on 112 patients. Leuk Res 2010;
34: 1430–6.
14 Greenberg PL, Sun Z, Miller KB et al. Treatment of
myelodysplastic syndrome patients with erythropoietin with
or without granulocyte colony-stimulating factor: results of
a prospective randomized phase 3 trial by the Eastern
Cooperative Oncology Group (E1996). Blood 2009; 114:
2393–400.
15 de Swart L, Smith A, Johnston TW et al. Validation of
the revised international prognostic scoring system (IPSS-
R) in patients with lower-risk myelodysplastic syndromes:
a report from the prospective European
LeukaemiaNet MDS (EUMDS) registry. Br J Haematol
2015; 170: 372–83.
16 Cheson BD, Greenberg P, Bennett JM et al. Clinical applica-
tion and proposal for modification of the International Work-
ing Group (IWG) response criteria in myelodysplasia. Blood
2006; 108: 419–25.
17 Hellstr€om-Lindberg E, Ahlgren T, Beguin Y et al. Treatment of
anemia in myelodysplastic syndromes with granulocyte
colony-stimulating factor plus erythropoietin: results from a
randomized phase II study and long-term follow-up of 71
patients. Blood 1998; 92: 68–75.
18 Austin P. The use of propensity score methods with survival
or time-to-event outcomes: reporting measures of effect
similar to those used in randomized experiments. Stat Med
2014; 33: 1242–58.
19 Cole SR, Hernan M. Adjusted survival curves with inverse
probability weights. Comput Methods Programs Biomed 2004;
75: 45–9.
20 SSSI Inc. Software 14.1 User’s Guide TEC, NC: 2015.
21 Schemper M, Smith T. A note on quantifying follow-up
in studies of failure time. Control Clin Trials 1996; 17:
343–6.
22 World Economic and Financial Surveys World Economic
Outlook Database. http://www.imf.org/external/pubs/ft/
weo/2014/02/weodata/index.aspx; imf.org. 2015.
23 Germing U, Strupp C, K€undgen A et al. No increase in age-
specific incidence of myelodysplastic syndromes. Haemato-
logica 2004; 89: 905–10.
24 Bernasconi P, Klercy C, Boni M, Cavigliano PM, Dambruoso I,
Zappatore R. Validation of the new comprehensive cytoge-
netic scoring system (NCCSS) on 630 consecutive de novo
MDS patients from a single institution. Am J Hematol 2013;
88: 120–9.
25 Oliva EN, Nobile F, Alimena G et al. Darbepoetin alfa for the
treatment of anemia associated with myelodysplastic syn-
dromes: efficacy and quality of life. Leuk Lymphoma 2010; 51:
1007–14.
26 Goldberg SL, Chen E, Sasane M, Paley C, Guo A, Laouri M.
Economic impact on US Medicare of a new diagnosis of
myelodysplastic syndromes and the incremental costs asso-
ciated with blood transfusion need. Transfusion 2013; 52:
2131–8.
Correspondence: Hege K. G. Garelius, Section of Hematology and
Coagulation, Sahlgrenska University Hospital, Bruna straket 5,
413 45 G€oteborg, Sweden.
(fax: +4631820269; e-mail: hege.garelius@vgregion.se).
Supporting Information
Additional Supporting Information may be found in
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Data S1. Erythropoiesis stimulating agents sig-
nificantly delay the onset of a regular transfusion
need in previously non-transfused patients with
lower risk MDS and anemia. Supplementary infor-
mation.
Table S1 Days between the ‘before’ and ‘after’ ESA
visit and the start of ESA treatment and months
between these visits for patients with and without
haemoglobin-based response defined.
Figure S1 Changes in Hb values before and after
starting ESA among patients responding or not
responding to ESA treatment. Vertical reference
line denotes the start of ESA treatment and the
horizontal reference line denotes Hb = 10 g dL1.
(a) Hb against time to/since starting ESA among
Responders who had an increase in Hb of at least
1.5 g dL1 between the visits. Blue lines indicate
patients who changed from anaemic to non-anae-
mic, green lines those who remained anaemic and
red lines those who were initially non-anaemic. (b)
Hb against time to/since starting ESA among Non-
Responders.
Figure S2 Time between start of ESA treatment the
first post-ESA transfusion for patients who had
transfusions before starting ESA. Vertical reference
lines indicate (from left to right) start of ESA, end of
the first 8 weeks post-ESA and the end of week 16
post-ESA. Grey bars indicate patients who did not
have a visit at least 16 weeks after starting ESA,
blue bars indicate Non-Responders, red bar indi-
cate Responders.
Table S2 Hemoglobin-based response among all
ESA-treated patients.
Table S3 Estimated follow-up time in the study.
Figure S3 Kaplan-Meier estimates of ESA treat-
ment duration among patients with
Hb < 10 g dL1 when they started ESA stratified
by response status. Median duration among non-
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responders = 14.4 months and among respon-
ders = 31.4 months.
Table S4 Serum erythropoietin at the start of ESA
or at the first 2 visits for patients not receiving ESA
and transfusion experience up to the start of ESA
or to the first 2 visit for patients not treated with
ESA.
Table S5 Use of other MDS-specific treatments
relative to treatment with ESA. Before = first use
before ESA, With = evidence of overlap of the
treatments, After = evidence of treatment the start
of ESA.
Figure S4 Receiver-operator characteristic curve
for the logistic regression model of the propensity
to receive ESA treatment. A total of 484 treated and
413 untreated patients were included. Covariates
as listed in Tables S1 and S2.
Table S6 Results of v2 and t-tests comparing ESA
treated patients to patients not treated with ESA
with and without weighting by the propensity
scores.
Table S7 Summary hazard ratio estimates based
on 25 imputed datasets carried through the
analysis.
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